Market Overview:
The global paediatric vaccine market is expected to grow at a CAGR of 7.8% from 2018 to 2030. The growth in the paediatric vaccine market can be attributed to factors such as rising incidence of infectious diseases, increasing awareness about vaccination, and technological advancements in the field of paediatric vaccines. Based on type, the global paediatric vaccine market is segmented into pneumococcal vaccines, varicella vaccines, combination vaccines, poliovirus vaccines, hepatitis B virus (HBV) vaccines, measles-mumps-rubella (MMR)vaccines,, Haemophilus influenzae type b (HIB)vaccines,, allergy and respiratory disease vaccines,, and other pediatrician vaccinessuch as rotavirus and meningococcal conjugate vaccine. Pneumococcal Vaccinesegment is projected to grow at the highest CAGR during the forecast period owingto increasing incidence of pneumonia across the globe. Based on application ,the global pediatrician vaccinemarketis segmented into age group 0-3 years old , 3-12 years oldand above 12 years old . Age group 0-3years olds areexpectedtogrowat themost rapidCAGRand reach a valueof US$ XX millionby2030 .
Product Definition:
A paediatric vaccine is a vaccine specifically designed to protect infants and young children from disease. Many vaccines are not recommended for use in paediatrics, such as the shingles vaccine, because they have not been tested in children. The importance of paediatric vaccines is that they protect children from diseases that can cause serious illness or death.
Pneumococcal:
Pneumococcal is a vaccine for prevention of pneumonia caused by the bacteria Streptococcus pneumonia. Pneumonia can be life-threatening and requires immediate medical attention. The Centers for Disease Control and Prevention (CDC) recommends routine vaccination against pneumococcal infections in children, especially those who are at risk of developing severe disease or infection.
Varicella:
Varicella is a highly contagious virus and can be transmitted through air by cough, sneeze or even just plain contact with another infected person. The disease has two main stages namely primary and secondary.
Application Insights:
The age group 0-3 years held the largest share of 26.1% in 2017 in the global Paediatric vaccine market. This is due to high immunization coverage against a number of diseases such as DTP, measles, and polio among other vaccines. Immunization programs are carried out during initial months of life against a number of diseases to ensure complete protection from disease onset by providing antibodies generated before exposure to infectious agents.
Immunization at an early age provides lifelong immunity and reduces mortality & morbidity caused by these infections worldwide which is anticipated to propel demand over the forecast period for this segment globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to factors such as high healthcare expenditure, favorable government initiatives, and increasing awareness about vaccines among parents. For instance, according to a study published by the Centers for Disease Control & Prevention (CDC) in 2016; pneumococcal vaccine is recommended for all children between 2 and 23 months old and again between 5 and 21 years of age.
Growth Factors:
- Increasing incidence of infectious diseases in children
- Growing awareness about the benefits of vaccination among parents
- Rising demand for pediatric vaccines from emerging countries
- Technological advancements in vaccine development and manufacturing processes
- Expansion of global public-private partnerships for vaccine development
Scope Of The Report
Report Attributes
Report Details
Report Title
Paediatric Vaccine Market Research Report
By Type
Pneumococcal, Varicella, Combinations, Poliovirus, Hepatitis , MMR , Pediatric Hormones    , HIB, Allergy and Respiratory vaccines, Other Pediatric vaccines
By Application
Age (0-3), Age (3-12), Age Above 12
By Companies
GlaxoSmithCline, Merck, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Eli Lilly, Pfizer, F. Hoffmann-La Roche, Novo Nordisk
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Paediatric Vaccine Market Report Segments:
The global Paediatric Vaccine market is segmented on the basis of:
Types
Pneumococcal, Varicella, Combinations, Poliovirus, Hepatitis , MMR , Pediatric Hormones    , HIB, Allergy and Respiratory vaccines, Other Pediatric vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Age (0-3), Age (3-12), Age Above 12
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithCline
- Merck
- Sanofi
- Bristol-Myers Squibb
- Abbott Laboratories
- Eli Lilly
- Pfizer
- F. Hoffmann-La Roche
- Novo Nordisk
Highlights of The Paediatric Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pneumococcal
- Varicella
- Combinations
- Poliovirus
- HepatitisÂ
- MMRÂ
- Pediatric Hormones   Â
- HIB
- Allergy and Respiratory vaccines
- Other Pediatric vaccines
- By Application:
- Age (0-3)
- Age (3-12)
- Age Above 12
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Paediatric Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Paediatric vaccines are vaccines that are specifically designed for use in children. They include vaccines against diseases such as diphtheria, tetanus, pertussis (whooping cough), polio, and measles.
Some of the major companies in the paediatric vaccine market are GlaxoSmithCline, Merck, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Eli Lilly, Pfizer, F. Hoffmann-La Roche, Novo Nordisk.
The paediatric vaccine market is expected to register a CAGR of 7.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Paediatric Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Paediatric Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Paediatric Vaccine Market - Supply Chain
4.5. Global Paediatric Vaccine Market Forecast
4.5.1. Paediatric Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Paediatric Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Paediatric Vaccine Market Absolute $ Opportunity
5. Global Paediatric Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Paediatric Vaccine Market Size and Volume Forecast by Type
5.3.1. Pneumococcal
5.3.2. Varicella
5.3.3. Combinations
5.3.4. Poliovirus
5.3.5. Hepatitis
5.3.6. MMR
5.3.7. Pediatric Hormones
5.3.8. HIB
5.3.9. Allergy and Respiratory vaccines
5.3.10. Other Pediatric vaccines
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Paediatric Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Paediatric Vaccine Market Size and Volume Forecast by Application
6.3.1. Age (0-3)
6.3.2. Age (3-12)
6.3.3. Age Above 12
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Paediatric Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Paediatric Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Paediatric Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Paediatric Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Paediatric Vaccine Demand Share Forecast, 2019-2029
9. North America Paediatric Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Paediatric Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Paediatric Vaccine Market Size and Volume Forecast by Application
9.4.1. Age (0-3)
9.4.2. Age (3-12)
9.4.3. Age Above 12
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Paediatric Vaccine Market Size and Volume Forecast by Type
9.7.1. Pneumococcal
9.7.2. Varicella
9.7.3. Combinations
9.7.4. Poliovirus
9.7.5. Hepatitis
9.7.6. MMR
9.7.7. Pediatric Hormones
9.7.8. HIB
9.7.9. Allergy and Respiratory vaccines
9.7.10. Other Pediatric vaccines
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Paediatric Vaccine Demand Share Forecast, 2019-2029
10. Latin America Paediatric Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Paediatric Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Paediatric Vaccine Market Size and Volume Forecast by Application
10.4.1. Age (0-3)
10.4.2. Age (3-12)
10.4.3. Age Above 12
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Paediatric Vaccine Market Size and Volume Forecast by Type
10.7.1. Pneumococcal
10.7.2. Varicella
10.7.3. Combinations
10.7.4. Poliovirus
10.7.5. Hepatitis
10.7.6. MMR
10.7.7. Pediatric Hormones
10.7.8. HIB
10.7.9. Allergy and Respiratory vaccines
10.7.10. Other Pediatric vaccines
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Paediatric Vaccine Demand Share Forecast, 2019-2029
11. Europe Paediatric Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Paediatric Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Paediatric Vaccine Market Size and Volume Forecast by Application
11.4.1. Age (0-3)
11.4.2. Age (3-12)
11.4.3. Age Above 12
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Paediatric Vaccine Market Size and Volume Forecast by Type
11.7.1. Pneumococcal
11.7.2. Varicella
11.7.3. Combinations
11.7.4. Poliovirus
11.7.5. Hepatitis
11.7.6. MMR
11.7.7. Pediatric Hormones
11.7.8. HIB
11.7.9. Allergy and Respiratory vaccines
11.7.10. Other Pediatric vaccines
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Paediatric Vaccine Demand Share, 2019-2029
12. Asia Pacific Paediatric Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Paediatric Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Paediatric Vaccine Market Size and Volume Forecast by Application
12.4.1. Age (0-3)
12.4.2. Age (3-12)
12.4.3. Age Above 12
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Paediatric Vaccine Market Size and Volume Forecast by Type
12.7.1. Pneumococcal
12.7.2. Varicella
12.7.3. Combinations
12.7.4. Poliovirus
12.7.5. Hepatitis
12.7.6. MMR
12.7.7. Pediatric Hormones
12.7.8. HIB
12.7.9. Allergy and Respiratory vaccines
12.7.10. Other Pediatric vaccines
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Paediatric Vaccine Demand Share, 2019-2029
13. Middle East & Africa Paediatric Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Paediatric Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Paediatric Vaccine Market Size and Volume Forecast by Application
13.4.1. Age (0-3)
13.4.2. Age (3-12)
13.4.3. Age Above 12
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Paediatric Vaccine Market Size and Volume Forecast by Type
13.7.1. Pneumococcal
13.7.2. Varicella
13.7.3. Combinations
13.7.4. Poliovirus
13.7.5. Hepatitis
13.7.6. MMR
13.7.7. Pediatric Hormones
13.7.8. HIB
13.7.9. Allergy and Respiratory vaccines
13.7.10. Other Pediatric vaccines
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Paediatric Vaccine Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Paediatric Vaccine Market: Market Share Analysis
14.2. Paediatric Vaccine Distributors and Customers
14.3. Paediatric Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithCline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Sanofi
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Abbott Laboratories
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eli Lilly
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. F. Hoffmann-La Roche
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novo Nordisk
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
